1-3 of 3
Melanie M. Frigault
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Jennifer R. Diamond, Valentina Boni, Emerson Lim, Grzegorz Nowakowski, Raul Cordoba, Daniel Morillo, Ray Valencia, Isabelle Genvresse, Claudia Merz, Oliver Boix, Melanie M. Frigault, Joy M. Greer, Ahmed M. Hamdy, Xin Huang, Raquel Izumi, Harvey Wong, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1285–1293.
https://doi.org/10.1158/1078-0432.CCR-21-3617
Published: 01 April 2022
View article titled, First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
Open the PDF for First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity

Hui K. Gan, Michael Millward, Ye Hua, Chuan Qi, Yang Sai, Weiguo Su, Jian Wang, Lilin Zhang, Melanie M. Frigault, Shethah Morgan, Liu Yang, Jason D. Lickliter
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4924–4932.
https://doi.org/10.1158/1078-0432.CCR-18-1189
Published: 15 August 2019
View article titled, First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
Open the PDF for First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Alwin G. Schuller, Evan R. Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin A. Clark, Celina M. D'Cruz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (12): 2811–2819.
https://doi.org/10.1158/1078-0432.CCR-14-2685
Published: 14 June 2015
View article titled, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Open the PDF for The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models in another window
Includes: Supplementary data